Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on October 23, 2025
Definitive Healthcare Announces Timing of Its Third Quarter 2025 Financial Results Conference Call and Webcast
FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter …
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or “Company”), a publicly-trading technology company majority owned by Faraday Future, today announced a strategic partnership with BitGo, the …
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with …
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) models BBO-11818’s selectivity for KRAS demonstrated by its > …
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the …
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, …
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 …
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly has the right to designate one …
Fall for Science: The Tech Interactive Unveils New Exhibits, Laser Shows, and Spooky STEAM Fun
San Jose, CA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Tech Interactive, Silicon Valley's premiere science and technology center, invites visitors to Fall for Science with a full lineup of innovation, imagination, and discovery. From brand-new exhibits and …
KZRex Exits U.S. Retail Market to Target Korea’s Crypto Elite in Bold Strategic Pivot
Singapore, Oct. 23, 2025 (GLOBE NEWSWIRE) -- KZRex, a Singapore-founded digital asset exchange known for its early mass-market success in the U.S., has announced a major strategic shift: a complete exit from retail operations in the West to focus …
Capital Links Investigates: Expert Legal Review of LuxUrban’s New York Tax Liability and OTA Compliance
New York, NY , Oct. 23, 2025 (GLOBE NEWSWIRE) -- An independent analysis by Capital Link of statutory law, audited filings, and the City of New York’s enforcement records confirms that LuxUrban Hotels Inc. is compliant with all applicable New York State …
FastBots.ai Reaches 73,000 Users as Small Businesses Turn to AI for Customer Service
London, UK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- FastBots.ai, a UK-based AI chatbot platform designed to simplify customer communication, today announced that it has reached 73,000 users since its founding in August 2023. The milestone highlights the growing …
Neue Untersuchung von Benevity Impact Labs deckt Vertrauenslücke unter globalen Geldgebern auf
CALGARY, Alberta, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Benevity Inc., der globale Anbieter von Social-Impact-Software, gab heute die Veröffentlichung eines erstmals vorgelegten Untersuchungsberichts bekannt, der sich mit dem Stand der unternehmerischen …
Une nouvelle étude de Benevity Impact Labs révèle un manque de confiance chez les subventionnaires internationaux
CALGARY, Alberta, 23 oct. 2025 (GLOBE NEWSWIRE) -- Benevity Inc., fournisseur mondial de logiciels d’impact social, a annoncé aujourd’hui la publication d’un rapport de recherche unique en son genre qui explore l’état des subventions accordées par les …
EdgeAI Wins Technology Frontier Award at 2025 Bincheng International Innovation & Entrepreneurship Competition
Singapore, Oct. 23, 2025 (GLOBE NEWSWIRE) -- EdgeAI, a next-generation AI and blockchain infrastructure startup, has been honored with the Technology Frontier Award at the 2025 Bincheng International Innovation …
Switching from Lead-Acid to Lithium Is Easier Than You Think. LiTime's One-Stop Upgrade Solutions Empower RV, Marine, and Other Users to Go Lithium with Ease
Shenzhen, China , Oct. 23, 2025 (GLOBE NEWSWIRE) -- Have you ever been held back by a lead-acid battery? On an RV trip, you set off fully charged but your lights dim in the night. Your fishing boat reaches the center of the lake, yet the battery “dies” …
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall response rate in gynecological cancers …
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC class …